Abstract
Although castration levels of serum androgens are consistently achieved after 2-3 weeks of treatment with luteinizing hormone-releasing hormone (LHRH) agonists, the administration of these peptides alone in adult men is always accompanied by a transient increase in plasma testosterone and dihydrotestosterone levels, which lasts for 5-15 days at the beginning of treatment and is accompanied by disease flare-up in some cases, thus seriously limiting the acceptability of this otherwise efficient and well-tolerated treatment. The present data show that the simultaneous administration of a pure antiandrogen neutralizes the influence of the transient increase in serum androgens on prostate cancer, as indicated by the 60% decrease in serum prostatic acid phosphatase observed within 5 days of combined treatment with an LHRH agonist and a pure antiandrogen. The addition of a pure antiandrogen thus makes fully acceptable the use of LHRH agonists as an advantageous substitute for surgical castration and estrogens in the treatment of prostate cancer.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Byar D. P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer. 1973 Nov;32(5):1126–1130. doi: 10.1002/1097-0142(197311)32:5<1126::aid-cncr2820320518>3.0.co;2-c. [DOI] [PubMed] [Google Scholar]
- Bélanger A., Caron S., Picard V. Simultaneous radioimmunoassay of progestins, androgens and estrogens in rat testis. J Steroid Biochem. 1980 Feb;13(2):185–190. doi: 10.1016/0022-4731(80)90190-9. [DOI] [PubMed] [Google Scholar]
- Labrie F., Dupont A., Belanger A., Cusan L., Lacourciere Y., Monfette G., Laberge J. G., Emond J. P., Fazekas A. T., Raynaud J. P. New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med. 1982;5(4):267–275. [PubMed] [Google Scholar]
- NESBIT R. M., BAUM W. C. Endocrine control of prostatic carcinoma; clinical and statistical survey of 1,818 cases. J Am Med Assoc. 1950 Aug 12;143(15):1317–1320. doi: 10.1001/jama.1950.02910500019005. [DOI] [PubMed] [Google Scholar]
- Resnick M. I., Grayhack J. T. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am. 1975 Feb;2(1):141–161. [PubMed] [Google Scholar]
- Tolis G., Ackman D., Stellos A., Mehta A., Labrie F., Fazekas A. T., Comaru-Schally A. M., Schally A. V. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658–1662. doi: 10.1073/pnas.79.5.1658. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Trachtenberg J. The treatment of metastatic prostatic cancer with a potent luteinizing hormone releasing hormone analogue. J Urol. 1983 Jun;129(6):1149–1152. doi: 10.1016/s0022-5347(17)52615-4. [DOI] [PubMed] [Google Scholar]